Page 165 - Drug Class Review
P. 165
Drug Effectiveness Review Project
Authors and Year: Reisberg et al. 2003; Rive et al. 2004; Doody et al. 2004
memantine placebo 87% 84% 32% 18% 8% 10% 8% 10% No significant differences in adverse events Post randomization exclusions: NR Overall loss to follow-up: 28.2% Loss to follow-up differential high: No placebo memantine 33.3% 23.0% 17% 10% Page 113 of 205
ITT: Yes Yes NR Method not reported Fair
Final Report Update 1 ADVERSE EVENTS: Overall adverse effects reported: Agitation • Insomnia • Diarrhea • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
